1052 GMT - Merck KGaA's potential acquisition of SpringWorks Therapeutics could boost its cancer-treatment pipeline, but the profitability of the deal is questionable, Equita analyst Davide Marchesin says in a note. "Therapeutics is generating over 350 million euros of annual revenues and it is loss making, therefore one critical question would be if the acquisition would be accretive from year one," the analyst says. The German pharma company's acquisition of the U.S. biopharmaceutical company would be one of the biggest pharma deals for Merck in recent years, potentially amounting to around 4 billion euros with a peak sales potential of over 1.0 billion euros in a few years, he says. Merck's shares are up 0.4% at 135.45 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 11, 2025 05:52 ET (10:52 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。